Ms. Bevers brings 30 years pharmaceutical biotechnology industry experience to DTx

SAN DIEGO,  DTx Pharma, Inc. (DTx), a privately-held biotechnology corporation growing novel RNA-based therapeutics to deal with the genetic drivers of disease, introduced nowadays the appointment of Denise Bevers as Chief Operating Officer.  In this role, Ms. Bevers will oversee a extensive vary of operational areas such as company strategy, investor relations, enterprise development, and medical operations.

 

"Denise joins our crew at some point of an interesting time at DTx.  Her a long time of ride in beginning and financing companies, and constructing profitable groups and pipelines, will enhance our management and assist us realise the full viable of our fatty acid conjugate science platform," stated Arthur T. Suckow, Co-Founder and CEO of DTx Pharma.  "Denise's demonstrated music file and sturdy scientific acumen aligns properly with our dreams as we proceed to make investments in our platform and improve more than one RNA-based treatment options towards the health center for genetically-defined diseases.  We welcome her to the DTx crew and seem ahead to her contributions."

Ms. Bevers brings over 30 years of pharmaceutical and biotechnology enterprise trip to DTx, with vast drug improvement know-how and a records of constructing clinical, business and manufacturing teams.  Prior to becoming a member of DTx, Ms. Bevers served as President & COO of Kindred Biosciences, a veterinary biopharmaceutical employer that she co-founded in 2012 and performed an necessary function in the company's Initial Public Offering (IPO) in 2013. Previously, Ms. Bevers used to be President & Founding Partner of SD Scientific and held administration positions at Elan Pharmaceuticals, SkyePharma, Quintiles, and Scripps Clinic and Research Foundation. Currently, Ms. Bevers serves on the Board of Directors of KindredBio, Hilltop Bio and on the Board of Trustees of the La Jolla Playhouse.

"I am delighted to be a part of DTx at this vital second in the company's records and I seem to be ahead to being a phase of its promising future. The company's skilled team, novel FALCON science platform, and the conceivable to seriously change an whole classification of drugs, make this a compelling opportunity," stated Ms. Bevers.  "The advances that DTx has made in the quick time for the reason that its inception role the organization to be a important participant in the RNA therapeutics field."